2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Neoadjuvant chemotherapy for invasive bladder cancer, involving a regimen of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC), can improve the resectability of larger neoplasms for some patients and offer a better prognosis. However, some suffer severe adverse drug reactions without any effect, and no method yet exists for predicting the response of an individual patient to chemotherapy. Our purpose in this study is to establish a method for predicting response to the M-VAC therapy.

          Related collections

          Author and article information

          Journal
          Clin Cancer Res
          Clinical cancer research : an official journal of the American Association for Cancer Research
          American Association for Cancer Research (AACR)
          1078-0432
          1078-0432
          Apr 01 2005
          : 11
          : 7
          Affiliations
          [1 ] Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
          Article
          11/7/2625
          10.1158/1078-0432.CCR-04-1988
          15814643
          75b3ff61-aecc-4f7a-beb9-059dca312e09
          History

          Comments

          Comment on this article